Efficacy of antisense monocyte chemoattractant protein-1 (MCP-1) in a rat model of mesangial proliferative glomerulonephritis

References

• Li LS, Liu ZH. Epidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsies. Kidney Int. 2004;66(3):920–923
   PubMed Web of Science ®Google Scholar
• Cove-Smith A, Hendry BM. The regulation of mesangial cell proliferation. Nephron Exp Nephrol. 2008;108(4):e74–e79
   Google Scholar
• Iyoda M, Shibata T, Kawaguchi M, et al. IL-17A and IL-17F stimulate chemokines via MAPK pathways (ERK1/2 and p38 but not JNK) in mouse cultured mesangial cells: synergy with TNF-alpha and IL-1beta. Am J Physiol. 2010;298(3):F779–F787
   Google Scholar
• Hisada Y, Sakurai H, Sugaya T. Cell to cell interaction between mesangial cells and macrophages induces the expression of monocyte chemoattractant protein-1 through nuclear factor-kappa B activation. Biochem Biophys Res Commun. 2000;269(2):309–316
   PubMed Web of Science ®Google Scholar
• Janssen U, Sowa E, Marchand P, Floege J, Phillips AO, Radeke HH. Differential expression of MCP-1 and its receptor CCR2 in glucose primed human mesangial cells. Nephron. 2002;92(4):797–806
   PubMed Web of Science ®Google Scholar
• Sharma K, Ziyadex FN. Hyperglycaemia and diabetic kidney disease: the case for transforming growth factor-β1 as a key mediator. Diabetes. 1995;44:1139–1146
   PubMed Web of Science ®Google Scholar
• Ban CR, Twigg SM. Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers. Vasc Health Risk Manag. 2008;4(3):575–596
   PubMedGoogle Scholar
• Chen S, Jim B, Ziyadeh FN. Diabetic nephropathy and transforming growth factor-beta: transforming our view of glomerulosclerosis and fibrosis build-up. Semin Nephrol. 2003;23(6):532–543
   PubMed Web of Science ®Google Scholar
• Yevdokimova N, Wahab NA, Mason RM. Thrombospondin-1 is the key activator of TGF-β1 in human mesangial cells exposed to high glucose. J Am Soc Nephrol. 2001;12(4):703–712
   PubMed Web of Science ®Google Scholar
• Poncelet AC, Schnaper HW, Tan R, Liu Y, Runyan CE. Cell phenotype-specific down-regulation of Smad3 involves decreased gene activation as well as protein degradation. J Biol Chem. 2007;282(21):15534–15540
   PubMed Web of Science ®Google Scholar
• Cristovam PC, Carmona AK, Arnoni CP, Maquigussa E, Pereira LG, Boim MA. Role of chymase indiabetic nephropathy. Exp Biol Med (Maywood). 2012;237(8):985–992
   PubMed Web of Science ®Google Scholar
• Ketteler M, Westenfeld R, Gawlik A, de Heer E, Distler A. Acute glomerular upregulation of ornithine decarboxylase is not essential for mesangial cell proliferation and matrix expansion in anti-Thy-1-nephritis. Nephrol Dial Transplant. 2000;15(1):16–22
   PubMed Web of Science ®Google Scholar
• Jefferson JA, Johnson RJ. Experimental mesangial proliferative glomerulonephritis (the anti-Thy-1.1 model). J Nephrol. 1999;12:297–307
   PubMed Web of Science ®Google Scholar
• Ausubel F, Brent R, Kingston RE. Short Protocols in Molecular Biology. Beijing: Science Press; 1998
   Google Scholar
• World Medical Association, American Physiological Society. Guiding principles for research involving animals and human beings. Am J Physiol. 2002;283(2):R281–R283
   Google Scholar
• , Working Group of the International IgA ephropathy Network and the Renal Pathology SocietyRoberts IS, Cook HT, et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 2009;76(5):546–556
   PubMed Web of Science ®Google Scholar
• , Working Group of the International IgA Nephropathy Network and the Renal Pathology SocietyCattran DC, Coppo R, Cook HT, et al. The Oxford classification of IgA nephropathy: rationale clinicopathological correlations, and classification. Kidney Int. 2009;76(5):534–545
   PubMed Web of Science ®Google Scholar
• Feehally J, Barratt J, Coppo R, et al. International IgA nephropathy network clinico-pathological classification of IgA nephropathy. Contrib Nephrol. 2007;157:13–18
   PubMed Web of Science ®Google Scholar
• D'Amico G. Influence of clinical and histological features on actuarial renal survival in adult patients with idiopathic IgA nephropathy, membranous nephropathy, and membranoproliferative glomerulonephritis: survey of the recent literature. Am J Kidney Dis. 1992;20(4):315–323
   PubMed Web of Science ®Google Scholar
• Woo KT, Chan CM, Mooi CY, et al. The changing pattern of primary glomerulonephritis in Singapore and other countries over the past 3 decades. Clin Nephrol. 2010;74(5):372–383
   PubMed Web of Science ®Google Scholar
• Ishizaki M, Sato S, Sano J, et al. The presence of Thy 1.1 antigen in rat glomerular mesangial cells. Biomed Res. 1980;1:438–442
   Web of Science ®Google Scholar
• Hohenstein B, Daniel C, Wittmann S, Hugo C. PDE-5 inhibition impedes TSP-1 expression, TGF-beta activation and matrix accumulation in experimental glomerulonephritis. Nephrol Dial Transplant. 2008;23(11):3427–3436
   PubMed Web of Science ®Google Scholar
• Panzer U, Steinmetz OM, Turner JE, et al. Resolution of renal inflammation: a new role for NF-kappa B1 (p50) in inflammatory kidney diseases. Am J Physiol. 2009;297(2): F429–F439
   Google Scholar
• Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res. 2009;29(6):313–326
   PubMed Web of Science ®Google Scholar
• Segerer S, Cui Y, Hudkins KL, et al. Expression of the chemokine monocyte chemoattractant protein-1 and its receptor chemokine receptor 2 in human crescentic glomerulonephritis. J Am Soc Nephrol. 2000;11(12):2231–2242
   PubMed Web of Science ®Google Scholar
• Vielhauer V, Anders HJ, Mack M, et al. Obstructive nephropathy in the mouse: progressive fibrosis correlates with tubulointerstitial chemokine expression and accumulation of CC chemokine receptor 2- and 5-positive leukocytes. J Am Soc Nephrol. 2001;12(6):1173–1187
   PubMed Web of Science ®Google Scholar
• Paul LC, Rennke HG, Milford EL, Carpenter CB. Thy-1.1 in glomeruli of rat kidneys. Kidney Int. 1984;25:771–777
   PubMed Web of Science ®Google Scholar
• Rennke HG, Anderson S, Brenner BM. The progression of renal disease: structural, and functional correlations. In: Tisher CC, Brenner BM, eds. Renal Pathology. Philadelphia, PA: Lippincott; 1994:116
   Google Scholar
• Karihaloo A, Koraishy F, Huen SC, et al. Macrophages promote cyst growth in polycystic kidney disease. J Am Soc Nephrol. 2011;22(10):1809–1814
   PubMed Web of Science ®Google Scholar
• Zhu XY, Chade AR, Krier JD, et al. The chemokine monocyte chemoattractant protein-1 contributes to renal dysfunction in swine renovascular hypertension. J Hypertens. 2009;27(10):2063–2073
   PubMed Web of Science ®Google Scholar
• Shimizu S, Nakashima H, Masutani K, et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates nephritis in MRL/lpr mice. Rheumatology (Oxford). 2004;43(9):1121–1128
   PubMed Web of Science ®Google Scholar
• Brujin JA, Roos A, de Geus B, de Heer E. Transforming growth factor-β and the glomerular extracellular matrix in renal pathology. J Lab Clin Med. 1994;123:34–47
   PubMed Web of Science ®Google Scholar
• Border WA, Noble NA. TGF-beta in kidney fibrosis: a target for gene therapy. Kidney Int. 1997;51:1388–1396
   PubMed Web of Science ®Google Scholar
• Kashiwagi M, Shinozaki M, Hirakata H, et al. Locally activated rennin–angiotensin system associated with TGF-beta1 as a major factor for renal injury induced by chronic inhibition of nitric oxide synthase in rats. J Am Soc Nephrol. 2000;11(4):616–624
   PubMed Web of Science ®Google Scholar
• Border WA, Okuda S, Languino LR, et al. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature. 1990;346(6282):371–374
   PubMed Web of Science ®Google Scholar
• Nilsen-Hamilton M. Transforming growth factor-beta and its action on cellular growth and differentiation. Curr Top Dev Biol. 1990;24:95–136
   PubMedGoogle Scholar
• Lawrance IC, Maxwell L, Doe W. Inflammation location, but not type, determines the increase in TGF-beta1 and IGF-1 expression and collagen deposition in IBD intestine. Inflamm Bowel Dis. 2001;7(1):16–26
   PubMed Web of Science ®Google Scholar
• Huang XR, Chung AC, Zhou L, Wang XJ, Lan HY. Latent TGF-beta1 protects against crescentic glomerulonephritis. J Am Soc Nephrol. 2008;19(2):233–242
   PubMed Web of Science ®Google Scholar
• Qian L, Wei SJ, Zhang D, et al. Potent anti-inflammatory and neuroprotective effects of TGF-beta1 are mediated through the inhibition of ERK and p47phox-Ser345 phosphorylation and translocation in microglia. J Immunol. 2008;181(1):660–668
   PubMed Web of Science ®Google Scholar
• Dai C, Wen X, He W, Liu Y. Inhibition of proinflammatory RANTES expression by TGF-beta1 is mediated by glycogen synthase kinase-3beta-dependent beta-catenin signaling. J Biol Chem. 2011;286(9):7052–7059
   PubMed Web of Science ®Google Scholar